Pharsight

Drugs that contain Terlipressin Acetate

1. Terlivaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-406) Sep 14, 2029
New Chemical Entity Exclusivity(NCE) Sep 14, 2027

NCE-1 date: 14 September, 2026

Market Authorisation Date: 14 September, 2022

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

TERLIVAZ family patents

Family Patents